

August 14, 2020



# Lantern Pharma Interview to Air on Bloomberg International on the RedChip Money Report

DALLAS, Aug. 14, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR<sup>®</sup> artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, today announced that an interview with its CEO and President Panna Sharma will air on *The RedChip Money Report* television program. The interview will air Sunday, August 16, 2020 at 6 p.m. local time on Bloomberg International, available in 100+ million homes across Europe.



In the exclusive interview, Sharma discusses the Company's innovative A.I.-based drug discovery and development platform, how it is being actively deployed, and current clinical testing underway.

To view the interview segment, please [click here](#).

The interview will also air in the U.S. on the Action Channel on Sunday, August 16, 2020 at 11 a.m. ET and is available via on demand stream on American Business TV.

"The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

**About Lantern Pharma**

Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at [www.lanternpharma.com](http://www.lanternpharma.com) or follow the company on Twitter @lanternpharma.

Contact:

Marek Ciszewski, JD  
Director, Investor Relations  
628-777-3167

### **Forward-looking Statements**

This press release and the interview referenced in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: the potential advantages of our RADR<sup>®</sup> platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates; estimates regarding the development timing for our drug candidates; our strategic plans to expand the number of data points that our RADR<sup>®</sup> platform can access and analyze; our research and development efforts of our internal drug discovery programs and the utilization of our RADR<sup>®</sup> platform to streamline the drug development process; and our intention to leverage artificial intelligence, machine learning and genomic data to streamline the drug development process and to identify patient populations that would likely respond to a drug candidate. Any statements that are not statements of historical fact (including, without limitation, statements to the effect that Lantern Pharma Inc. or our management "believes," "expects," "anticipates," "estimates," "plans" (and similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as the impact of the COVID-19 pandemic, the results of our clinical trials, and the impact of competition. Additional factors can be found in the Risk Factors section in our final prospectus, dated June 10, 2020, for our initial public offering, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus under the investor SEC filings tab of our website at [www.lanternpharma.com](http://www.lanternpharma.com) or on the SEC's website at [www.sec.gov](http://www.sec.gov). Given these risks and

uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements made by us in this press release or in the interview referenced in this press release represent our judgment as of the date of such statement, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

📄 View original content to download multimedia <http://www.prnewswire.com/news-releases/lantern-pharma-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-301112622.html>

SOURCE Lantern Pharma